13:46 , Mar 26, 2019 |  BC Extra  |  Clinical News

Aldeyra's allergic conjunctivitis therapy clears Phase III hurdle

Aldeyra shares rose $2.57 (36%) to $9.71 on Tuesday after the company said both doses of reproxalap (ADX-102) met the primary endpoint in the Phase III ALLEVIATE trial to treat allergic conjunctivitis. The small molecule...
22:38 , Mar 19, 2019 |  BC Extra  |  Company News

Management tracks: Medicines Co., Mallinckrodt, ArQule

The Medicines Co. (NASDAQ:MDCO) terminated the employment of Christopher Cox, EVP and chief corporate development officer, effective March 15. Details were not disclosed. Mallinckrodt plc (NYSE:MNK) hired Bryan Reasons as CFO. He will succeed interim...
23:46 , Jan 15, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore gains second ex-AZ exec

Immunocore Ltd. (Abingdon, U.K.) said it hired David Berman in September as head of R&D. Berman was SVP and head of immuno-oncology at AstraZeneca plc (LSE:AZN; NYSE:AZN), and before that was head of early stage...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:51 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Sept. 27, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in...
21:25 , Sep 28, 2018 |  BC Extra  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
17:33 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate...
16:53 , Sep 26, 2018 |  BC Extra  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans...
20:52 , Jul 31, 2018 |  BC Extra  |  Company News

Management tracks: Canbridge, Retrophin

Canbridge Life Sciences Ltd. (Beijing, China) hired May Orfali as CMO. She succeeds interim CMO Mark Goldberg. Orfali was executive director of global product development at Pfizer Inc. (NYSE:PFE). Rare disease company Retrophin Inc. (NASDAQ:RTRX)...
21:20 , May 11, 2018 |  BC Extra  |  Company News

Management tracks: Synlogic, Akari

Synlogic Inc. (NASDAQ:SYBX) said President and CEO Jose Carlos Gutiérrez-Ramos has resigned. CMO Aoife Brennan will serve as interim president and CEO while the synthetic biology company seeks a successor. Autoimmune and inflammatory disease company...